Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Regeneron week: AERIFY-1 COPD results posted; new cenvacibart, alirocumab, cemiplimab trials filedOct 16Weekly roundup, 6 itemsalirocumabcemiplimab-rwlcUpdated
Regeneron registers Phase 1b hemodialysis study, Phase 1 Graves' disease trialOct 9Weekly roundup, 6 itemsamrecibartbortezomib
Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure resultsOct 2Weekly roundup, 5 itemsALN-CIDEBamrecibartUpdated
Regeneron registers Phase 1b trial of Factor XI/XII antibodies in dialysis patientsAug 12Trial updateamrecibartcenvacibart
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Regeneron registers Phase 3 PICC clot-prevention trial; Sanofi runs sarilumab study as collaboratorJul 17Weekly roundup, 3 itemsamrecibartcenvacibart